Article Text

Download PDFPDF

4 Atlas™ stent assisted anterior circulation aneurysm coiling: one year outcomes
  1. O Zaidat1,
  2. R Hanel2,
  3. E Sauvageau2,
  4. A Aghaebrahim2,
  5. E Lin1,
  6. A Jadhav3,
  7. T Jovin4,
  8. A Khaldi5,
  9. R Gupta5,
  10. A Johnson5,
  11. D Frei6,
  12. D Loy6,
  13. A Malek7,
  14. G Toth8,
  15. A Siddiqui9,
  16. J Reavey-Cantwell10,
  17. A Thomas11,
  18. S Hetts12,
  19. B Jankowitz13
  1. 1Neuroscience Department, Bon Secours Mercy Health St. Vincent Medical Center, Toledo, OH
  2. 2Lyerly Neurosurgery, Jacksonville, FL
  3. 3Neurology, UPMC Presbyterian Hospital, Pittsburgh, PA
  4. 4Cooper University Hospital Neurological Institute, Camden, NJ
  5. 5Neurosurgery, WellStar Kennestone Hospital, Marietta, GA
  6. 6Radiology and Medical Imaging, University of Virginia, Charlottesville, VA
  7. 7Neurosurgery, Tufts Medical Center, Boston, MA
  8. 8Cleveland Clinic Foundation, Cleveland, OH
  9. 9SUNY University at Buffalo, Buffalo, NY
  10. 10Virginia Commonwealth University Medical Center, Richmond, VA
  11. 11Beth Israel Deaconess Medical Center, Boston, MA
  12. 12Interventional Neuroradiology, The University of California San Francisco, San Francisco, CA
  13. 13Neurological Surgery, UPMC Presbyterian Hospital, Pittsburgh, PA


Background and purpose Stent-assisted coil embolization using the new generation Neuroform Atlas™ Stent System has shown promising technical, safety, and clinical feasibility and efficacy. Here, we present the one year angiographic and efficacy results of the anterior circulation cohort in the ATLAS Investigational Device Exemption (IDE) Trial.

Methods ATLAS IDE is a prospective, multicenter, single-arm, open label study of unruptured wide-necked (neck ≥4 mm or dome-to-neck ratio <2) intracranial aneurysms in the anterior circulation treated with the Neuroform Atlas Stent and approved coils. The primary efficacy endpoint was complete aneurysm occlusion (Raymond class I) on 12-month angiography, in the absence of retreatment, or parent artery stenosis >50% at the target location. The primary safety endpoint was any major stroke or ipsilateral stroke or neurological death within 12 months. Adjudication of the primary endpoints was performed by an imaging core laboratory and the Clinical Events Committee for ATLAS.

Results A total of 182 patients with unruptured wide-necked anterior circulation aneurysms at 25 US centers were enrolled. The mean age was 60.3±11.4 years, 73.1% (133/182) women, and 80.8% (147/182) Caucasian. Mean aneurysm size and dome-to-neck ratio was 6.1±2.2 mm and 1.2±0.3, respectively. Sixty-four (35.2%) aneurysms were located in the anterior communicating artery. Mean procedure duration was 110.2±47.0 minutes. Technical success was achieved in 100% (182/182) of patients. Follow-up imaging data at 12 months was available in 84.1% (153/182) of patients. The primary efficacy endpoint was achieved in 84.7% [95%CI: 78.6,90.9] of subjects and the incidence of primary safety endpoint failure was 4.4% (8/182; 95%CI: 1.9, 8.5).

Conclusion In the ATLAS IDE anterior circulation cohort pre-market approval study, the Neuroform ATLAS stent with adjunctive coiling demonstrated high rates of long-term complete occlusion at 12 months, with excellent technical success and safety.

Disclosures O. Zaidat: None. R. Hanel: None. E. Sauvageau: None. A. Aghaebrahim: None. E. Lin: None. A. Jadhav: None. T. Jovin: None. A. Khaldi: None. R. Gupta: None. A. Johnson: None. D. Frei: None. D. Loy: None. A. Malek: None. G. Toth: None. A. Siddiqui: None. J. Reavey-Cantwell: None. A. Thomas: None. S. Hetts: None. B. Jankowitz: None.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.